Immune Checkpoint Inhibitor-associated Gastrointestinal Adverse Events in Patients with Colorectal Cancer

Overview

Journal Ann Gastroenterol

Date 2025 Jan 13

PMID 39802282

Authors

Antonio Pizuorno Machado

Saltenat Moghaddam Adames

Malek Shatila

Parvir Aujla

Ryan Huey

Yinghong Wang

Anusha Thomas

Affiliations

Soon will be listed here.

Abstract

Background: Immune checkpoint inhibitors (ICI) target microsatellite instability-high (MSI-H) tumors with success. The incidence and characteristics of ICI-related colitis (IMC) in patients with MSI-H colorectal cancers (CRC) are unclear.

Methods: We performed a retrospective analysis of adult patients with CRC who received ICI between June 1, 2014, and December 31, 2022, including data on IMC observed up to 3 months after the last dose of ICI. Patients' demographics, oncologic profile, endoscopic features, treatment and clinical outcomes were evaluated.

Results: Of 474 patients with CRC receiving ICI during our study period, 18 developed IMC (3.8%). The majority were Caucasian (88.8%), male (61.1%), and their median age was 69.5 years. Of these patients, 50% received combination therapy with anti-PD-1/L1 and CTLA-4; 66.6% had MSI-H colorectal cancer, 11.1% had a second cancer-melanoma, while 61.2% and 66.7% had grade 1-2 colitis and diarrhea respectively. Endoscopic evaluation was used in 5 patients, of whom 2 had ulcerative inflammation necessitating selective immunosuppressive therapy with biologics. Therapy was withheld in 61.1% because of toxicity; 41.4% and 5.8% were noted to have median Common Terminology Criteria for Adverse Events grade 2 liver and pancreas toxicity respectively. The majority of our cohort received steroid therapy.

Conclusions: The lower severity of IMC, compared to toxicity in other ICI-treated cancers, may be influenced by the tumor microenvironment in MSI-H colorectal cancer after ICI exposure. Larger prospective studies are necessary to determine the role of tumor biology and the gut microbiome in the disease profile and severity of IMC.

References

Tran A, Wang M, Hundt M, Chugh R, Ohm J, Grimshaw A . Immune Checkpoint Inhibitor-associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies. J Immunother. 2021; 44(8):325-334. DOI: 10.1097/CJI.0000000000000383. View

Shivaji U, Jeffery L, Gui X, Smith S, Ahmad O, Akbar A . Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management. Therap Adv Gastroenterol. 2019; 12:1756284819884196. PMC: 6831976. DOI: 10.1177/1756284819884196. View

Yamamoto H, Imai K . Microsatellite instability: an update. Arch Toxicol. 2015; 89(6):899-921. DOI: 10.1007/s00204-015-1474-0. View

Blum S, Rouhani S, Sullivan R . Effects of immune-related adverse events (irAEs) and their treatment on antitumor immune responses. Immunol Rev. 2023; 318(1):167-178. DOI: 10.1111/imr.13262. View

Benson A, Venook A, Al-Hawary M, Arain M, Chen Y, Ciombor K . Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021; 19(3):329-359. DOI: 10.6004/jnccn.2021.0012. View

Rose L, DeBerg H, Vishnu P, Frankel J, Manjunath A, Flores J . Incidence of Skin and Respiratory Immune-Related Adverse Events Correlates With Specific Tumor Types in Patients Treated With Checkpoint Inhibitors. Front Oncol. 2021; 10:570752. PMC: 7844139. DOI: 10.3389/fonc.2020.570752. View

Zackular J, Rogers M, Ruffin 4th M, Schloss P . The human gut microbiome as a screening tool for colorectal cancer. Cancer Prev Res (Phila). 2014; 7(11):1112-21. PMC: 4221363. DOI: 10.1158/1940-6207.CAPR-14-0129. View

Jia W, Xie G, Jia W . Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol. 2017; 15(2):111-128. PMC: 5899973. DOI: 10.1038/nrgastro.2017.119. View

Khoja L, Day D, Wei-Wu Chen T, Siu L, Hansen A . Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017; 28(10):2377-2385. DOI: 10.1093/annonc/mdx286. View

10.

Som A, Mandaliya R, Alsaadi D, Farshidpour M, Charabaty A, Malhotra N . Immune checkpoint inhibitor-induced colitis: A comprehensive review. World J Clin Cases. 2019; 7(4):405-418. PMC: 6397821. DOI: 10.12998/wjcc.v7.i4.405. View

11.

Machado A, Shatila M, Liu C, Lu Y, Altan M, Glitza Oliva I . Characteristics, treatment, and outcome of patients with bowel perforation after immune checkpoint inhibitor exposure. J Cancer Res Clin Oncol. 2023; 149(9):5989-5998. DOI: 10.1007/s00432-022-04569-y. View

12.

Aggarwal V, Workman C, Vignali D . LAG-3 as the third checkpoint inhibitor. Nat Immunol. 2023; 24(9):1415-1422. PMC: 11144386. DOI: 10.1038/s41590-023-01569-z. View

13.

Andre T, Shiu K, Kim T, Jensen B, Jensen L, Punt C . Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020; 383(23):2207-2218. DOI: 10.1056/NEJMoa2017699. View

14.

Keir M, Butte M, Freeman G, Sharpe A . PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008; 26:677-704. PMC: 10637733. DOI: 10.1146/annurev.immunol.26.021607.090331. View

15.

Michot J, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S . Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016; 54:139-148. DOI: 10.1016/j.ejca.2015.11.016. View

16.

Nielsen D, Juhl C, Chen I, Kellermann L, Nielsen O . Immune checkpoint Inhibitor-Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis. Cancer Treat Rev. 2022; 109:102440. DOI: 10.1016/j.ctrv.2022.102440. View

17.

Das S, Johnson D . Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019; 7(1):306. PMC: 6858629. DOI: 10.1186/s40425-019-0805-8. View

18.

Gong Z, Wang Y . Immune Checkpoint Inhibitor-Mediated Diarrhea and Colitis: A Clinical Review. JCO Oncol Pract. 2020; 16(8):453-461. DOI: 10.1200/OP.20.00002. View

19.

Le D, Kim T, Van Cutsem E, Geva R, Jager D, Hara H . Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. J Clin Oncol. 2019; 38(1):11-19. PMC: 7031958. DOI: 10.1200/JCO.19.02107. View

20.

Larkin J, Del Vecchio M, Mandala M, Gogas H, Arance Fernandez A, Dalle S . Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238. Clin Cancer Res. 2023; 29(17):3352-3361. PMC: 10472092. DOI: 10.1158/1078-0432.CCR-22-3145. View